Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma

By Fabiana Negrin OchoaNovo Nordisk has signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion.The Danish drugmaker will pay China-based Hengrui $300 million upfront, with the rest of the potential deal value tied to milestones.N…